Onemednet Corp · NASDAQ:ONMD
Onemednet — SPAC Merger (May 2022)
28 slides from Onemednet's SPAC merger presentation, May 20, 2022
Slide 1: Extracting and Refining Medical Real World Data
Extracting and Refining Medical Real World Data P AUL C ASEY CEO J EFFREY Y U , MD F OUNDER & C HAIRMAN APRIL 2022 1
Slide 2: Confidential — Not for Distribution
‹#› C o nfi de ntial — N o t f or Di str ibuti on This presentation is for information purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between OneMedNet Corporation (“OneMedNet”) and Data Knights
Slide 3: Why Real World Data is Needed
‹#› C o nfi de ntial — N o t f or Di str ibuti on Why Real World Data is Needed Because Clinical Trials Are Very Artificial Very Limited Need REAL Data from the REAL World October 2018 FDA Mandates the Use of Imaging Real World Data January 2020 China FDA Publishes Real World Data Guidelines If COVI
Slide 4: Management
‹#› C o nfi de ntial — N o t f or Di str ibuti on Management 4 Data Knights Acquisition Corp. OneMedNet Barry Anderson Firdauz Edmin Mokhtar Jeffrey Yu Paul Casey Thomas Kosasa Erkan Aykuz Chairman & CEO CFO F o un d er / Chair man /CMO CEO & Board Director Board Director Board Director +15 years ex
Slide 5: Transaction Overview
‹#› C o nfi de ntial — N o t f or Di str ibuti on Transaction Overview OneMedNet is preparing to go public through a SPAC Merger with Data Knights Acquisition Corp. ● OneMedNet is a pioneer in medical image sharing and exchange technologies. OneMedNet has provid ed medical image sharing anywhere aro
Slide 6: Sources, uses and pro forma ownership
‹#› C o nfi de ntial — N o t f or Di str ibuti on SPAC Cash in Trust $117.3M Cash to Balance Sheet $113.2M Seller Rollover Equity $ 200M Seller Rollover Equity $200M PIPE Investment Pending Transaction Expenses $4.02M Total Sources $ 317.3M Total Uses $317.3M Share Pric e $10.00 Pro Forma Shares Out
Slide 7: Market Overview: Total Addressable Market
‹#› C o nfi de ntial — N o t f or Di str ibuti on Clinical Trials and Research > $404 B RWE $12B Market Overview Total Addressable Market ● Biopharma and medical device companies require insight - rich, high - quality patient data to fuel their development of novel therap eutics and devices. ● OneMe
Slide 8: Market Overview: Total Addressable Market
‹#› C o nfi de ntial — N o t f or Di str ibuti on Clinical Trial Market Real World - Evidence The Real - World Data Market size was valued at $47.0B in 2021, expected to grow at CAGR of 5.8% from 2022 to 2030 2020 TAM is estimated at $37.2B, expected to grow to $62.6B by 2028 with a 7.6% CAGR 2021 T
Slide 9: Investment Highlights
‹#› C o nfi de ntial — N o t f or Di str ibuti on $61M 2026 Bookings iRWD ONLY Provider of Regulatory Grade Imaging Real World Data (iRWD) on Demand 65M+ Studies High barriers to entry: Largest volume and geographic coverage of regulatory grade data and secret sauce indexing and data curation techni
Slide 10: Largest Volume and Diversity of Regulatory Grade Data
‹#› C o nfi de ntial — N o t f or Di str ibuti on Largest Volume and Diversity of Regulatory Grade Data Radiology Cardiology Orthopedics Neurology Oncology Woman’s Health Dentistry Pathology Ophthalmology OneMedNet has the knowledge, tools, and experience to access and harmonize complete patient pro
Slide 11: Key Differentiators
‹#› C o nfi de ntial — N o t f or Di str ibuti on Key Differentiators Regulatory Grade Our imaging results serve as proof of effectiveness for regulatory agencies, meeting requirements for quality and diversity On Demand Our powerful indexing platform access and harmonizes complete patient profiles
Slide 12: Competitive Advantages
‹#› C o nfi de ntial — N o t f or Di str ibuti on Competitive Advantages 65M Medical Imaging Studies ● Many contain full longitudinal record ( orders, images, reports, EMR data ) ● 20M more coming soon through new data partnerships ● On track for critical mass of 100M studies Highly Qualified Curati
Slide 13: Go-To-Market
‹#› C o nfi de ntial — N o t f or Di str ibuti on Go - To - Market ? Imaging AI ● RWD completely replaces clinical trials for AI , eliminating dependency on onerous prospective data collection to obtain and curate data to train, tune & validate AI models ● Simultaneously pursue multiple use cases wi
Slide 14: Real-World Data Market Value
‹#› C o nfi de ntial — N o t f or Di str ibuti on 14 Regulatory Grade Raw Data Claims Add Clinical Records (EMR) Add Imaging + Reports Add Genotype (Genomic Data) Data Richness Add Pathology Add Longitudinal (Patient Data Over Time) Data Specificity / Curation $ Real - World Data Market Value
Slide 15: Key Strategic Partners & Customers
‹#› C o nfi de ntial — N o t f or Di str ibuti on Key Strategic Partners & Customers Sources Strategic Direct Channel 15 Global Health Care Companies
Slide 16: Land and Expand
‹#› C o nfi de ntial — N o t f or Di str ibuti on $3M - 5M+ $2M - 5M+ • Post - market surveillance • Multiple pharma projects • Retrospective & Prospective • Interventional & No Intervention • Federated Data ‘Store’ • iRWD Referral Orders • Flywheel Platform Referrals High Value Opportunities Land a
Slide 17: Opportunity Review: Company A
‹#› C o nfi de ntial — N o t f or Di str ibuti on Opportunity Review C ompany A - Training Data Project In Negotiation $3,000,000 Company A - New AI Sourcing Partner (training data) In Negotiation $1,000,000 Company A - CTPA for PE rule in/out, Puneet In Negotiation $135,000 Company A - Liver CT for
Slide 18: Case Study: Global Health Care Company A
‹#› C o nfi de ntial — N o t f or Di str ibuti on Validated by Key Strategic Partners 29 Case Study: Global Health Care Company A Land - and - Expand Validation Data Low to average Volume Detailed data collection protocols Expert clinical data curation Price: $$$ Training Data High volume Minimal da
Slide 19: Opportunity Review: Global Health Care Company B
‹#› C o nfi de ntial — N o t f or Di str ibuti on Company B - Post Market Surveillance Prospecting $1,000,000 Company B - Real World Surveillance Prospecting $1,000,000 Company B - Post Market Surveillance POC Evaluating $250,000 Company B - Data Innovation team (POC) Evaluating $250,000 Company B -
Slide 20: Case Study: Regulatory Grade Data with Google
‹#› C o nfi de ntial — N o t f or Di str ibuti on Key Differentiators Google developed a breast cancer mammography imaging AI algorithm, promoting a study on the performance on their AI as diagnostic breast cancer more accurately than radiologists’ Scientists took the study to task, including the us
Slide 21: BEAM connects the entire country of Ireland
‹#› C o nfi de ntial — N o t f or Di str ibuti on 21 BEAM connects the entire country of Ireland Change Healthcare has deployed OneMedNet’s BEAM into ALL public and private hospitals of Ireland connecting the entire country’s healthcare system into a single network (43 public and 25 private hospital
Slide 22: Case Study: Channel Strategy with Flywheel
‹#› C o nfi de ntial — N o t f or Di str ibuti on Validated by Key Strategic Partners Case Study: Channel Strategy with Flywheel Flywheel provides an imaging centric platform for research, academic and pharma to mine and analyze clinical trail data • Flywheel is partnering with OneMedNet to infuse m
Slide 23: Mature Pipeline of iRWD Deals
‹#› C o nfi de ntial — N o t f or Di str ibuti on Mature Pipeline or iRWD Deals 41 Imaging AI 32 Med Device 22 Pharma & CRO 135 Deals in PIPELINE $21.9M year 1 ACV Growing Deal Size Pharmaceutical Device Imaging AI Clinical Research Org. Healthcare Providers 23
Slide 24: Native and Partner Data Coverage
‹#› C o nfi de ntial — N o t f or Di str ibuti on Native and Partner Data Coverage 24 Data Available via OneMedNet Data Sites Under Development
Slide 25: OneMedNet Board
‹#› C o nfi de ntial — N o t f or Di str ibuti on OneMedNet Board Jeffrey Yu F o un d er / Chair man/CMO OneMedNet ● Founder & Chairman: Kineticor ● CTO: The Queens Health System ● Chief of Radiology / Diagnostics Queens Health System ● Tiger 21 Member Orlando ● Mallinckrodt Institute of Radiology ●
Slide 26: Enterprise Value / Revenue Valuation Benchmarking
‹#› C o nfi de ntial — N o t f or Di str ibuti on Enterprise Value / Revenue Valuation Benchmarking 29 15.17x 18.95x 20.02x 14.64x 26.33x 15.66x 30.14x 11.36x 13.01x 14.33x NA 20.24x 12.90x 11.02x Avg. 20.13x Avg. 13.81x Enterprise Value: $200 M 23.26X 10.75X Source: FactSet Fundamentals, FactSet Es
Slide 27: Industry Comps
‹#› C o nfi de ntial — N o t f or Di str ibuti on Industry Comps Data from Crunchbase 27 $2.28B Valuation $2.6B Unknown $1.9B $328M Total Funding $281M $195M $300M 65x Revenue Multiple 32.5x Infinite 26x 6 Years Period 7 Years 1.5 Years 1.5 Years 250 Oncology Clinics Notes BI and Data Visualization
Slide 28: ONGCMCEONGET
ONGCMCEONGET wre llal oe ln